Cognitive dysfunction in multiple sclerosis: The effect of pharmacological interventions

References

• Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: A reappraisal after 10 years. Archives of Neurology 2001; 58: 1602–1606
   PubMed Web of Science ®Google Scholar
• Amato MP, Portaccio E, Zipoli V. Are there protective treatments for cognitive decline in MS?. Journal of the Neurological Sciences 2006; 245: 183–186
   PubMed Web of Science ®Google Scholar
• Audoin B, Ibarrola D, Ranjeva JP, Confort-Gouny S, Malikova I, Ali-Chérif A, et al. Compensatory cortical activation observed by fMRI during a cognitive task at the earliest stage of MS. Human Brain Mapping 2003; 20: 51–58
   PubMed Web of Science ®Google Scholar
• Baddeley Á. Working memory. Science 1992; 255: 556–559
   PubMed Web of Science ®Google Scholar
• Ballard CG. Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition (review). European Neurology 2002; 47: 64–70
   PubMed Web of Science ®Google Scholar
• Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. European Neurology 2002; 47: 11–14
   PubMed Web of Science ®Google Scholar
• Benedict RHB, Fischer JS, Archibald CJ, Arnett PA, Beatty WW, Bobholz J, et al. Minimal neuropsychological assessment of MS patients: A consensus approach. The Clinical Neuropsychologist 2002; 16: 381–397
   PubMed Web of Science ®Google Scholar
• Benedict RH, Bruce JM, Dwyer MG, Abdelrahman N, Hussein S, Weinstock-Guttman B, et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Archives of Neurology 2006; 63: 1301–1306
   PubMed Web of Science ®Google Scholar
• Benedict RH, Munschauer F, Zarevics P, Erlanger D, Rowe V, Feaster T, et al. Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. Journal of Neurology 2008; 255: 848–852
   PubMed Web of Science ®Google Scholar
• Benedict RH, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R. Prediction of neuropsychological impairment in multiple sclerosis: Comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Archives of Neurology 2004; 61: 226–230
   PubMed Web of Science ®Google Scholar
• Borras C, Porcel J, Brieva L, Tintoré M, Rio J, Arévalo MJ, et al. Neuropsychological performance in patients with primary and transitional progressive multiple sclerosis treated with interferon beta-1b. Multiple Sclerosis 2003; 9: S144
   Google Scholar
• Cader S, Palace J, Matthews P. Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis. Journal of Psychopharmacology 2009; 23: 686–696
   PubMed Web of Science ®Google Scholar
• Calabrese P. Neuropsychology of multiple sclerosis: An overview. Journal of Neurology 2006; 253: 10–15
   PubMed Web of Science ®Google Scholar
• Carone DA, Benedict RH, Dwyer MG, Cookfair DL, Srinivasaraghavan B, Tjoa CW, et al. Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS. Neuroimage 2006; 29: 505–514
   PubMedGoogle Scholar
• Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679–687
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221–1231
   PubMed Web of Science ®Google Scholar
• D’Intino G, Paradisi M, Fernandez M, Giuliani A, Aloe L, Giardino L, et al. Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proceedings of the National Academy of Science USA 2005; 102: 3070–3075
   PubMed Web of Science ®Google Scholar
• European Study Group. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998; 352: 1491–1497
   PubMed Web of Science ®Google Scholar
• Feinstein A. Mood disorders in multiple sclerosis and the effects on cognition. Journal of the Neurological Sciences 2006; 245: 63–66
   PubMed Web of Science ®Google Scholar
• Feinstein A. The neuropsychiatry of multiple sclerosis. Canadian Journal of Psychiatry 2004; 49: 157–163
   PubMed Web of Science ®Google Scholar
• Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Annals of Neurology 2000; 48: 885–892
   PubMed Web of Science ®Google Scholar
• Flechter S, Vardi J, Finkelstein Y, Pollak L. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: An open-label prospective 1 year study. The Israel Medical Association Journal 2007; 9: 457–459
   PubMed Web of Science ®Google Scholar
• Gerschlager W, Beisteiner R, Deecke L, Dirnberger G, Endl W, Kollegger H, et al. Electrophysiological, neuropsychological and clinical findings in multiple sclerosis patients receiving interferon beta-1b: A one-year follow-up. European Neurology 2000; 44: 205–209
   PubMedGoogle Scholar
• Ghaffar O, Feinstein A. The neuropsychiatry of multiple sclerosis: A review of recent developments. Current Opinion in Psychiatry 2007; 20: 278–285
   PubMed Web of Science ®Google Scholar
• Goshen I, Kreisel T, Ounallah-Saad H, Renbaum P, Zalzstein Y, Ben-Hur T, et al. A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology 2007; 32: 1106–1115
   PubMed Web of Science ®Google Scholar
• Heldt SA, Stanek L, Chhatwal JP, Ressler KJ. Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Molecular Psychiatry 2007; 12: 656–670
   PubMed Web of Science ®Google Scholar
• Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A three-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389–397
   PubMed Web of Science ®Google Scholar
• Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004; 63: 1579–1585
   PubMed Web of Science ®Google Scholar
• Lazeron RH, Boringa JB, Schouten M, Uitdehaag BM, Bergers E, Lindeboom J, et al. Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. Multiple Sclerosis 2005; 11: 524–531
   PubMed Web of Science ®Google Scholar
• Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Annals of Neurology 1999; 46: 197–206
   PubMed Web of Science ®Google Scholar
• Lin X, Tench CR, Morgan PS, Constantinescu CS. Use of combined conventional and quantitative MRI to quantify pathology related to cognitive impairment in multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry 2008; 79: 437–441
   PubMedGoogle Scholar
• Lovera J, Bagert B, Smoot K, Morris CD, Frank R, Bogardus K, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: A randomized, placebo-controlled trial. Multiple Sclerosis 2007; 13: 376–385
   PubMed Web of Science ®Google Scholar
• Parry AM, Scott RB, Palace J, Smith S, Matthews PM. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 2003; 126: 2750–2760
   PubMed Web of Science ®Google Scholar
• Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 662–667
   PubMed Web of Science ®Google Scholar
• Paulesu E, Frith CD, Frackowiak RSJ. The neural correlates of the verbal component of working memory. Nature 1993; 362: 342–344
   PubMed Web of Science ®Google Scholar
• Penner IK, Opwis K, Kappos L. Relation between functional brain imaging, cognitive impairment and cognitive rehabilitation in patients with multiple sclerosis. Journal of Neurology 2007; 254: SII53–SII57
   Google Scholar
• Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, Noronha A, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996; 47: 1463–1468
   PubMed Web of Science ®Google Scholar
• Porcel J, Montalban X. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis. Journal of the Neurological Sciences 2006; 245: 177–181
   PubMed Web of Science ®Google Scholar
• Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: Impact on employment and social functioning. Neurology 1991; 41: 692–696
   PubMed Web of Science ®Google Scholar
• Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP, The Copaxone Study Group. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. Journal of the Neurological Sciences 2007; 255: 57–63
   PubMed Web of Science ®Google Scholar
• Selby MJ, Ling N, Williams JM, Dawson A. Interferon beta 1-b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis. Perceptual and Motor Skills 1998; 86: 1099–1106
   PubMedGoogle Scholar
• Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Canadian Journal of Neurological Sciences 2008; 35: 476–481
   PubMed Web of Science ®Google Scholar
• Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Annals of Neurology 1998; 43: 79–87
   PubMed Web of Science ®Google Scholar
• Stadelmann C, Kerschensteiner M, Misgeld T, Brück W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: Neuroprotective interactions between immune and neuronal cells?. Brain 2002; 125: 75–85
   PubMed Web of Science ®Google Scholar
• Staffen WA, Mair H, Zauner A, Unterrainer J, Niederhofer H, Kutzelnigg A, et al. Cognitive function and fMRI in patients with multiple sclerosis: Evidence for compensatory cortical activation during an attention task. Brain 2002; 125: 1275–1282
   PubMed Web of Science ®Google Scholar
• Tekok-Kilic A, Benedict RH, Weinstock-Guttman B, Dwyer MG, Carone D, Srinivasaraghavan B, et al. Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. Neuroimage 2007; 36: 1294–1300
   PubMed Web of Science ®Google Scholar
• Villoslada P, Arrondo G, Sepulcre J, Alegre M, Artieda J. Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009; 72: 1630–1633
   PubMed Web of Science ®Google Scholar
• Weinstein A, Schwid SR, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Archives of Neurology 1999; 56: 319–324, Erratum in: Archives of Neurology (2004) 61, 1284
   PubMed Web of Science ®Google Scholar
• Zéphir H, de Seze J, Dujardin K, Dubois G, Cabaret M, Bouillaguet S, et al. One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. Multiple Sclerosis 2005; 11: 360–363
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 2001a; 70: 773–780
   PubMed Web of Science ®Google Scholar
• Zivadinov VR, De Masi D, Nasuelli LM, Bragadin LM, Ukmar M, Pozzi-Mucelli RS, et al. MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis. Neuroradiology 2001b; 43: 272–278
   PubMed Web of Science ®Google Scholar